Sanket Koul

At least 2-3 more foreign universities to open campuses in India this year

Indian drugmakers are reviewing shipment schedules and inventories for West Asia as escalating tensions threaten sea and air routes, raising freight costs and risking supply delays

Gaurs Group will invest Rs 250 crore to build a precast and modular construction facility in Noida after signing an MoU with Elematic India, aiming to boost efficiency and project timelines

TARC will prioritise Delhi and Gurugram in FY27 with phased launches across existing luxury projects, backed by strong demand momentum and projected cash-flow visibility over four years

Abbott will commercialise Extensior, a second semaglutide brand of Ozempic in India, as part of Novo Nordisk's strategy to expand access amid rising demand and looming patent expiry

NBCC has signed two MoUs with DDA for redeveloping staff colonies at Old Rajinder Nagar and Safdarjung Development Area, securing Rs 775 crore in projects under a self-sustainable model

CDSCO will permit drugmakers to begin testing samples as soon as applications are filed, shifting detailed scrutiny to later stages to shorten approval timelines and ease compliance

A Knight Frank-Deloitte report says foreign universities establishing campuses in India could help retain $113 billion in foreign currency by 2040, easing large outflows for overseas education

Eris Lifesciences partners with Natco Pharma to commercialise semaglutide in India in 2026, as rising demand and impending patent expiry fuel intense competition in metabolic and weight-loss therapies

India will launch a nationwide, free and voluntary HPV vaccination campaign for 14-year-old girls, using Gardasil under strict quality norms, as part of efforts to eliminate cervical cancer

Firms upbeat as Delhi-Meerut RRTS now fully operational

Gurugram has surpassed Mumbai in luxury housing sales for the first time in five years, driven by HNI demand, new micro-markets and major infrastructure upgrades, a new report shows

Morepen Labs has secured a ₹825 crore multi-year CDMO mandate from a global pharma major, with supplies set to begin in 4-5 months and execution running through Q1 FY27

Indian auto and medical device exporters adopt wait-and-watch approach as US tariff shifts and refund uncertainty cloud shipment decisions

The decision follows the company's settlement with IDBI Trusteeship Services; the NCLT order further records that all pending applications in the matter stand disposed of

Ind-Ra says Indian drugmakers will still see 10% revenue growth in FY27 driven by domestic demand and CDMO traction, despite weaker US sales after Revlimid expiry

Premiumisation of housing fuels demand for larger units, with NCR, Chennai and Bengaluru posting the sharpest gains in average apartment sizes over two years

Macron announced plans to triple the number of Indian students in France and launched an Indo-French AI health centre, as both nations deepen cooperation in AI, mobility and nuclear R&D

Central Park will invest ₹1,200 crore in its new ultra-luxury Belanova project in Gurugram, targeting sales of up to ₹3,000 crore with phased pricing and strong early demand

AIOCD has urged the Prime Minister to ban AI-generated prescriptions, alleging they are being misused by unregulated e-pharmacies to sell restricted medicines, posing a serious public health risk